---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-062807"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:46:50.422182+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aditxt CEO presents at investor event; updates on Evofem close, Pearsanta commercialization, crypto strategy

## Summary
- CEO Amro Albanna presented at Wall Street Reporter's Next Super Stock livestream on July 8, 2025, discussing business model as 'publicly owned innovation accelerator'.
- Pearsanta validation ongoing; expects to commercialize prostate cancer and endometriosis tests by Q1 2026.
- Evofem acquisition (women's health) expected to close by end of September 2025, subject to financing, as anchor for Adifem.
- Announced Bitcoin/crypto treasury strategy to broaden shareholder base; market cap ~$5M.
- Adimune plans to file for human trials Q4 2025/Q1 2026 for stiff person syndrome, type 1 diabetes, psoriasis.

## SEC filing metadata
- accession: 0001213900-25-062807
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390025062807/0001213900-25-062807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390025062807/ea0248501-8k_aditxt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-062807
- JSON: https://secwatch.observer/filing/0001213900-25-062807.json
- Plain text: https://secwatch.observer/filing/0001213900-25-062807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.